81_FR_35894 81 FR 35787 - Government-Owned Inventions; Availability for Licensing

81 FR 35787 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 107 (June 3, 2016)

Page Range35787-35787
FR Document2016-13112

The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.

Federal Register, Volume 81 Issue 107 (Friday, June 3, 2016) 
[Federal Register Volume 81, Number 107 (Friday, June 3, 2016)]
[Notices]
[Page 35787]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-13112]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below, may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD 20850-9702, Tel. 240-276-5515 or email 
[email protected]. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Chimeric Antigen Receptors to CD276 for 
treating Cancer.
    Description of Technology: Chimeric antigen receptors (CARs) are 
hybrid proteins consisting of an antibody binding fragment fused to 
protein signaling domains that cause T-cells which express the CAR to 
become cytotoxic. Once activated, these cytotoxic T-cells can 
selectively eliminate the cells which they recognize via the antibody 
binding fragment of the CAR. By engineering a T-cell to express a CAR 
that is specific for a certain cell surface protein, it is possible to 
selectively target those cells for destruction. This is a promising new 
therapeutic approach known as adoptive cell therapy.
    CD276 (a.k.a., B7-H3) is a tumor-associated antigen that is 
expressed on the cell surface of several cancers, including 
neuroblastomas, prostate cancer, ovarian cancer and some lung cancers. 
This technology concerns the development of CARs comprising an antigen-
binding fragment derived from the MGA271 antibody. The resulting CARs 
can be used in adoptive cell therapy treatment for neuroblastoma and 
other tumors which express CD276.
    Potential Commercial Applications:
     Treatment of cancers associated with expression of CD276.
     Specific cancers include neuroblastoma, prostate cancer, 
ovarian cancer, lung cancer and other solid tumors.
    Value Proposition:
     MGA271 is a well characterized anti-CD276 antibody, making 
it a known quantity regarding safety issues.
     High affinity of the MGA271 antibody for CD276 increases 
the likelihood of successful targeting.
     Targeted therapy decreases non-specific killing of 
healthy, essential cells, resulting in fewer non-specific side-effects 
and healthier patients.
    Development Stage: Discovery (Lead ID).
    Inventor(s): Crystal Mackall.
    Intellectual Property: HHS No. E-243-2015/0-US-01 U.S. Provisional 
Application 62/216,447 (E-243-2015/0-US-01) filed 9/10/2015 titled 
``Anti-CD276 Chimeric Antigen Receptors''.
    Publications: None applicable.
    Collaboration Opportunity: Researchers at the NCI seek licensing 
for chimeric antigen receptors to CD276 for treating cancer.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: [email protected].

    Dated: May 31, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-13112 Filed 6-2-16; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 107 / Friday, June 3, 2016 / Notices 35787 Written Comments: For Tribes: the close of the comment period to all eliminate the cells which they recognize consultation@ihs.gov. Tribal governments and interested via the antibody binding fragment of the For Urbans: urbanconfer@ihs.gov. urban Indian organizations within the CAR. By engineering a T-cell to express FOR FURTHER INFORMATION CONTACT: Great Plains Area. a CAR that is specific for a certain cell CAPT Chris Buchanan, Acting Director, Dated: May 27, 2016. surface protein, it is possible to Great Plains Area, Indian Health Mary Smith, selectively target those cells for Service, 115 4th Ave. SE Suite 309 Principal Deputy Director, Indian Health destruction. This is a promising new Aberdeen, South Dakota, (605) 226– Service. therapeutic approach known as 7584, Fax (605) 226–7541. [FR Doc. 2016–13135 Filed 6–2–16; 8:45 am] adoptive cell therapy. SUPPLEMENTARY INFORMATION: These BILLING CODE 4165–16–P CD276 (a.k.a., B7–H3) is a tumor- meetings are in follow-up to the April associated antigen that is expressed on 5–7, 2016 IHS Tribal Leaders Briefing in the cell surface of several cancers, Sioux Falls, South Dakota. The IHS DEPARTMENT OF HEALTH AND including neuroblastomas, prostate would like to invite the Great Plains HUMAN SERVICES cancer, ovarian cancer and some lung Area Tribal Leaders to participate in cancers. This technology concerns the formal consultation and interested National Institutes of Health development of CARs comprising an urban Indian organizations to confer antigen-binding fragment derived from Government-Owned Inventions; the MGA271 antibody. The resulting with IHS leadership to discuss the state Availability for Licensing CARs can be used in adoptive cell of the Great Plains Area IHS. The purpose of these sessions are to AGENCY: National Institutes of Health, therapy treatment for neuroblastoma receive feedback on the organization of HHS. and other tumors which express CD276. the IHS Great Plains Area Office in an ACTION: Notice. Potential Commercial Applications: effort to continue to become more • Treatment of cancers associated patient-focused in order to better meet SUMMARY: The invention listed below is with expression of CD276. the needs of the American Indians in owned by an agency of the U.S. Government and is available for • Specific cancers include the Great Plains Area. Specific topics licensing and/or co-development in the neuroblastoma, prostate cancer, ovarian will include geographic location of the U.S. in accordance with 35 U.S.C. 209 cancer, lung cancer and other solid Great Plains Area Office, centralization and 37 CFR part 404 to achieve tumors. or further decentralization of area office services, staffing, budget, local expeditious commercialization of Value Proposition: involvement, transparency and results of federally-funded research and • MGA271 is a well characterized oversight, partnerships, accountability, development. Foreign patent anti-CD276 antibody, making it a known and monitoring. applications are filed on selected quantity regarding safety issues. Tribal leaders and designated inventions to extend market coverage • High affinity of the MGA271 representatives as well as urban Indian for companies and may also be available antibody for CD276 increases the organizations that are interested in for licensing and/or co-development. likelihood of successful targeting. submitting written testimony for the on- ADDRESSES: Invention Development and • Targeted therapy decreases non- site or telephonic consultation and Marketing Unit, Technology Transfer specific killing of healthy, essential urban confer sessions can provide Center, National Cancer Institute, 9609 cells, resulting in fewer non-specific written comments to the following: For Medical Center Drive, Mail Stop 9702, side-effects and healthier patients. Tribes—consultation@ihs.gov. For Rockville, MD 20850–9702. Development Stage: Discovery (Lead Urbans—urbanconfer@ihs.gov. FOR FURTHER INFORMATION CONTACT: ID). The Tribal consultation and urban Information on licensing and co- confer sessions will be conducted with development research collaborations, Inventor(s): Crystal Mackall. elected or appointed leaders of Tribal and copies of the U.S. patent Intellectual Property: HHS No. E–243– governments and their designated applications listed below, may be 2015/0–US–01 U.S. Provisional representatives [42 U.S.C. 9835, Section obtained by contacting: Attn. Invention Application 62/216,447 (E–243–2015/0– 640(l)(4)(A)], and recognized Development and Marketing Unit, US–01) filed 9/10/2015 titled ‘‘Anti- representatives from urban Indian Technology Transfer Center, National CD276 Chimeric Antigen Receptors’’. organizations, as defined by 25 U.S.C. Cancer Institute, 9609 Medical Center Publications: None applicable. 1603(29). Representatives from other Drive, Mail Stop 9702, Rockville, MD Collaboration Opportunity: Tribal organizations and Native non- 20850–9702, Tel. 240–276–5515 or Researchers at the NCI seek licensing for profit organizations are welcome to email ncitechtransfer@mail.nih.gov. A chimeric antigen receptors to CD276 for attend as observers. Those wishing to signed Confidential Disclosure treating cancer. participate in the discussions must have Agreement may be required to receive Contact Information: Requests for a copy of a letter signed by an elected copies of the patent applications. copies of the patent application or or appointed official or their designee, SUPPLEMENTARY INFORMATION: inquiries about licensing, research which authorizes them to serve as a Technology description follows. collaborations, and co-development representative of the Tribe. This should Title of invention: Chimeric Antigen opportunities should be sent to John D. be submitted no later than three days in Receptors to CD276 for treating Cancer. Hewes, Ph.D., email: advance of the Tribal consultation and Description of Technology: Chimeric mstockstill on DSK3G9T082PROD with NOTICES john.hewes@nih.gov. urban confer session to CAPT Chris antigen receptors (CARs) are hybrid Buchanan at (605) 226–7541 (fax). proteins consisting of an antibody Dated: May 31, 2016. A detailed report of all written binding fragment fused to protein John D. Hewes, comments and comments received signaling domains that cause T-cells Technology Transfer Specialist, Technology through the Tribal consultation and which express the CAR to become Transfer Center, National Cancer Institute. urban confer sessions will be prepared cytotoxic. Once activated, these [FR Doc. 2016–13112 Filed 6–2–16; 8:45 am] and made available within 90 days of cytotoxic T-cells can selectively BILLING CODE 4140–01–P VerDate Sep<11>2014 21:20 Jun 02, 2016 Jkt 238001 PO 00000 Frm 00055 Fmt 4703 Sfmt 9990 E:\FR\FM\03JNN1.SGM 03JNN1


Document Created: 2018-02-08 07:29:32
Document Modified: 2018-02-08 07:29:32
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactInformation on licensing and co- development research collaborations, and copies of the U.S. patent applications listed below, may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or email [email protected] A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
FR Citation81 FR 35787 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR